# SAL-0951 in the Treatment of Chemotherapy-induced Anemia in Patients With Non-myeloid Malignancies

> **NCT06737081** · PHASE2 · RECRUITING · sponsor: **Shenzhen Salubris Pharmaceuticals Co., Ltd.** · enrollment: 60 (estimated)

## Conditions studied

- Anemia

## Interventions

- **DRUG:** SAL-0951 tablets 4mg
- **DRUG:** SAL-0951 tablets 5mg

## Key facts

- **NCT ID:** NCT06737081
- **Lead sponsor:** Shenzhen Salubris Pharmaceuticals Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-09-14
- **Primary completion:** 2025-12-31
- **Final completion:** 2026-06-30
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2024-12-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06737081

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06737081, "SAL-0951 in the Treatment of Chemotherapy-induced Anemia in Patients With Non-myeloid Malignancies". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06737081. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*